Mon, Mar 31, 6:07 PM (27 days ago)
**Protagenic Therapeutics, Inc. (PTIX) Summary** **Financial Performance:** - **Revenue:** $0 (no revenue generated) - **Net Income:** -$5,525,344 (loss for 2024) - **Operating Expenses:** $5,700,950 (2024) - **Earnings per Share:** -$1.13 (basic and diluted, 2024) **Strategic Overview:** - **Lead Compound:** PT00114, a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP) - **Indications:** Depression, anxiety, substance abuse & addiction, and PTSD - **Mechanism:** Novel, leveraging TCAP's role in maintaining brain health under stress - **Clinical Trials:** Phase I completed, Phase II anticipated in 2026 **Future Outlook:** - **Development Milestones:** Rapidly advance PT00114, develop additional TCAP family compounds, explore new indications - **Partnerships:** Assess strategic partnerships, including international markets - **Funding:** Need to raise additional capital, currently sufficient until Q3 2025 **Risk Factors:** - **Financial Condition:** Significant operating losses, negative cash flow, reliance on external funding - **Clinical Development:** High risk of failure, regulatory approval uncertainty, dependence on third parties - **Commercialization:** No sales or marketing capabilities, reliance on third parties, market acceptance uncertainty - **Intellectual Property:** Dependence on exclusive license, potential challenges from competitors - **Operational:** Dependence on key personnel, growth management challenges, healthcare reform impacts **Financial Condition:** - **Cash:** $1,838,469 (2024) - **Working Capital:** $940,108 (2024) - **Funding:** Need to raise additional capital beyond Q3 2025 **Market Position Changes:** - **Competitive Landscape:** Few novel candidates in development, competition from major pharmaceutical companies - **Market Opportunity:** Large patient population, significant unmet medical need **Note:** All amounts are in thousands, $000s.